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The Bleeding Edge of Symptom Assessment
O ne of the most vexing problems for a pediatric hematolo-gist is the appropriate investigation of mild bleeding
symptoms. Bruising and epistaxis are typical features of child-
hood yet frequent reasons for referral, and are often difﬁcult to
quantify and precisely categorize as either normal or suspicious.
There are a signiﬁcant number of individuals in the general pop-
ulation who report non-speciﬁc bleeding symptoms [1], and this
certainly applies to parental accounts. While coagulation cascade
defects are relatively simple to identify by laboratory evaluation,
testing of von Willebrand factor (VWF) antigen and activity
levels are notoriously variable from examination to examination,
even in the same individual. There is also a large overlap in VWF
levels between individuals with von Willebrand disease (VWD)
and the normal human population [2,3]. Consequently it has been
estimated that there is a 0.4% prevalence of false-positive type 1
VWD [1]. Indeed prevalence estimates in children decreased from
1% to 0.1% when prescreening was done with a validated bleed-
ing questionnaire [4]. Therefore it is critical to avoid testing
unless there is signiﬁcant symptomatology, yet the criteria for
proceeding to laboratory analysis are not always clear.
Classically, diagnosis of VWD requires three components,
laboratory testing consistent with the disorder, bleeding symp-
toms, and a family history, although often only one of the latter
two is present upon initial consultation. Since a conservative
estimate is that roughly 25% of healthy controls have non-speciﬁc
bleeding symptoms [1], indiscriminate testing will continue to
produce false-positive results. Furthermore, the laboratory deﬁni-
tion of VWD has been revised by an NHLBI expert consensus
panel [5]. Deﬁnitive VWD is now primarily distinguished by a
ristocetin cofactor activity of less than 30%, while 30–50% is
classiﬁed as ‘‘low VWF.’’ Many clinicians currently treat these
patients with low VWF in the same manner as mild VWD, as the
precise bleeding risks for this group are not known at this time.
However, due to the variability of VWF testing, many initially
low VWF individuals are truly normal and subsequently test in
the normal range on repeated examinations. Therefore, it would
preferable if those individuals could be eliminated prior to testing
in order to avoid the associated stresses and costs of misdiagnosis,
as well as the accompanying iatrogenic risks when labeled with a
bleeding disorder.
Given these issues, development of validated quantitative or
qualitative bleeding criteria has been a signiﬁcant aim in the
hemostasis community for some time, and many studies have
been performed over the years for VWD (reviewed in Ref. 5).
The primary methodology has been questionnaires, such as the
Vicenza Bleeding Score and MCMDM-1VWD (Molecular and
Clinical Markers for the Diagnosis and Management of Type 1
VWD) [6,7]. However, these were primarily based on adult
patients, and a Pediatric Bleeding Questionnaire has been devel-
oped more recently [8,9].
In this issue of Pediatric Blood & Cancer, Sidonio et al.
describe a large retrospective evaluation of approximately 300
pediatric patients over a 5-year period that measured the preva-
lence of VWD and disorders of platelet function, as well as
determined if qualitative bleeding symptoms predicted these
diagnoses. The patients were referred by primary physicians or
surgeons, and the criteria were a subset from the Vicenza Bleed-
ing Score [7], including cutaneous and mucocutaneous bleeding,
surgical bleeding, and family history. The authors produced four
logistic regression models, both single and multiple variable, with
the goal of correlating bleeding symptoms with low VWF, VWD,
and/or a platelet function disorder. None of the odds ratios were
statistically signiﬁcant, and a subgroup analysis of adolescents
with menorrhagia was similarly non-prognostic.
In their discussion, the authors highlight that this is one of the
largest pediatric cohorts to be evaluated in this manner. However,
they acknowledge the limitations of their study, including its
retrospective use of a database that was not designed for this
analysis, pointing to the need for a prospective trial. This call
has recently been answered. Using the modiﬁed Vicenza Pediatric
Bleeding Questionnaire [9], a prospective study of approximately
100 children at an academic children’s hospital has been per-
formed [10]. The ﬁndings were similarly disappointing with the
exception of a high negative predictive value for exclusion of type
1 VWD. The primary limitation in that study was lack of stan-
dardization of the laboratory evaluation.
At this time additional prospective, standardized studies are
required if a useful predictive system is to be validated. The
unanswered question remains whether a pediatric bleeding ques-
tionnaire is attainable that will allow clinicians to reliably exclude
most unaffected children from the vagaries of VWF and platelet
laboratory evaluations. This is critical in order to avoid unneces-
sary diagnoses and interventions in otherwise healthy subjects.
Sidonio et al. suggest the need for a more systematic and quanti-
tative scoring system than employed in their study. However, this
will have to be balanced against the time commitment required
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for the evaluation of bleeding scores, and whether they are
dependent on skilled clinical support staff. The most efﬁcient
system will be one that can be performed with minimal cost
and/or time, either through the primary physician, or by a home
questionnaire or website administered remotely under the auspic-
es of a coagulation disorders program. With increasing demands
on the time of busy clinicians, there is the risk of defaulting to
automatic laboratory testing or referral with inadequate screening.
There is also a tendency to test patients who have traveled long
distances to referral centers, even if symptoms seem to be minor.
Despite these limitations, we must continue our attempts to de-
velop focused screening strategies. While the interventions for
minor bleeding disorders are relatively safe, there are still iatrogenic
risks, such as hyponatremia secondary to vasopressin, or infusion
of untreated human blood products in remote centers where factor
concentrates are unavailable. Patients with hemorrhagic disorders
are counseled to avoid collision sports and some parents may balk
at other less risky but healthy activities. If there is a 0.4% preva-
lence of false-positive VWD, the rates of true and false-positive
VWD cases may be equivalent. Therefore, in the absence of
appropriate symptomatic screening we will continue to mislabel
a large number of patients and put them at unnecessary risk.
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